Remedy Plan Therapeutics will bring a broad slate of AACR presentations centered on RPT1G, its “hyperbolic” NAMPT inhibitor now in an open-label, multi-center Phase 1 for relapsed/refractory AML and higher‑risk MDS (NCT07107126), alongside multiple preclinical combinations spanning PARP inhibitors, BCL2 targeting, standard chemotherapies, and pan‑RAS approaches across solid and hematologic tumors. The AACR lineup includes a Trials-in-Progress poster for the AML/MDS study and preclinical data in breast cancer, T‑ALL, pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, and rhabdomyosarcoma.
The core move is a coordinated effort to reframe NAMPT inhibition as clinically viable by emphasizing controlled enzymatic modulation rather than complete shutdown, a design Remedy Plan labels “hyperbolic” to address the on‑target toxicities that sidelined first‑generation agents. The company is simultaneously planting combination flags in well‑trafficked therapeutic territories: PARP inhibitor backbones in DNA damage repair–reliant tumors, venetoclax‑adjacent biology via BCL2 in T‑ALL, and RAS‑driven PDAC where metabolic dependency is acute. The mix of in‑house and academic-led abstracts suggests Remedy Plan is building translational breadth and KOL alignment ahead of decisive human efficacy signals.
Strategically, this is an expansion play with a hedge. Anchoring initial clinical development in AML/HR‑MDS gives an early read on hematologic tolerability and pharmacodynamics, while the preclinical portfolio broadcasts optionality in solid tumors where PARP and RAS combinations can open partnering doors. At the same time, the choice of a Trials‑in‑Progress update rather than an interim readout underscores that clinical proof remains ahead; the near‑term objective is to validate the mechanism, define a tolerable dose and schedule, and curate the most promising combination paths before committing to larger expansion cohorts.
For sites and CROs, the operational signal is twofold. First, the AML/HR‑MDS program will likely lean on intensive safety monitoring and pharmacodynamic sampling to demonstrate NAMPT target engagement, raising visit complexity and central lab dependencies. Second, the preclinical combination intent foreshadows protocol designs with overlapping myelosuppression risks (notably with PARP and BCL2 agents) and schedule coordination challenges that will test site capacity and AE attribution workflows. Vendors with robust PK/PD, NAD+ quantification, and biomarker assay capabilities should see opportunity, while networks with PARP or RAS inhibitor experience may be prioritized for early solid‑tumor studies.
Regulators will focus on whether “hyperbolic” inhibition translates into a materially wider therapeutic window than legacy NAMPT programs and whether clinical PD markers correlate with antitumor activity. Any move into combinations will face a high bar to demonstrate additive benefit without compounding hematologic or metabolic toxicity. The breadth of academic collaborations at AACR is useful for mechanistic credibility, but sponsors and payers will ultimately want clear, regimen‑level differentiation in defined populations rather than diffuse signals across many indications.
Next, watch for the first cut of Phase 1 safety, dose‑limiting toxicities, and target engagement data, along with a declared recommended Phase 2 dose and schedule. Equally important will be Remedy Plan’s prioritization choices: a PARP‑based solid‑tumor basket versus a hematologic triplet strategy that intersects with venetoclax‑based standards, each carrying distinct operational and commercial implications. Early partnering or co‑development signals with PARP or RAS incumbents would validate the combination thesis; absent that, the company will need crisp biomarker‑guided designs and disciplined indication selection to avoid dilution. The near‑term question is whether controlled NAMPT modulation can convert class‑wide promise into a tractable clinical program before larger players crowd the same metabolic real estate.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
